STK17B
Serine/Threonine Kinase 17B (DAP Kinase-Related Apoptosis-Inducing Protein Kinase 2)
Gene Information Card
| Symbol | STK17B |
|---|---|
| Full Name | Serine/Threonine Kinase 17B |
| Gene Type | Protein coding |
| Chromosomal Location | 2q32.3 |
| NCBI Gene ID | 9262 ncbi.nlm.nih.gov/gene/9262 |
| Ensembl ID | ENSG00000115977 |
| UniProt ID | O94768 |
| OMIM ID | 604726 |
| HGNC ID | 11396 |
| Aliases | DRAK2, STK17 |
Description
STK17B (Serine/Threonine Kinase 17B), also known as DRAK2 (DAP kinase-related apoptosis-inducing protein kinase 2), is a protein-coding gene that encodes a member of the death-associated protein (DAP) kinase family. The encoded protein is a nuclear serine/threonine kinase involved in apoptosis, cell cycle regulation, and immune response. It phosphorylates myosin light chain and plays a role in T-cell receptor-mediated apoptosis. STK17B is implicated in various cancers and autoimmune conditions.
Disease Associations
| Disease category | Pathophysiological mechanism | Genomic evidence |
|---|---|---|
| Breast cancer | Overexpression of STK17B promotes cell proliferation and resistance to apoptosis via kinase activity | COSMIC, PubMed |
| Colorectal cancer | STK17B upregulation correlates with poor prognosis and increased metastatic potential | COSMIC, PubMed |
| Autoimmune lymphoproliferative syndrome (ALPS) | Dysregulation of STK17B-mediated apoptosis contributes to lymphocyte accumulation | OMIM, PubMed |
| Hepatocellular carcinoma | STK17B silencing reduces tumor growth and induces apoptosis in vitro | COSMIC, PubMed |
Expression Profile
Tissue Expression
| Tissue | nTPM | level |
|---|---|---|
| Lymph node | 12.5 | Medium |
| Spleen | 10.3 | Medium |
| Bone marrow | 8.9 | Low |
| Testis | 7.2 | Low |
| Brain | 2.1 | Not detected |
Cell Line Expression
| Cell Line | nTPM | Notes |
|---|---|---|
| K-562 (leukemia) | 15.4 | High expression |
| HeLa (cervical cancer) | 9.8 | Moderate expression |
| A549 (lung cancer) | 6.5 | Low expression |
| MCF7 (breast cancer) | 11.2 | Moderate expression |
Data source：Human Protein Atlas（proteinatlas.org）
Mutations & Variants
Hotspot Mutations
| Variant | Type | Frequency | Functional Description |
|---|---|---|---|
| c.1015C>T (p.Arg339Trp) | Missense | <0.1% | Unknown functional impact; reported in COSMIC |
| c.1246G>A (p.Glu416Lys) | Missense | <0.1% | Predicted benign; ClinVar |
| c.1489_1490insA | Frameshift | <0.1% | Loss of function; COSMIC |
Mutation functional classification
Loss of Function (LOF)
Frameshift insertions (e.g., c.1489_1490insA) are predicted to truncate the kinase domain, impairing apoptotic signaling.
Gain of Function (GOF)
No confirmed gain-of-function mutations reported in curated databases.
Dominant Negative (DN)
No dominant-negative mutations described in ClinVar or COSMIC.
View complete mutation data：
Gene Ontology (GO)
Pathways
• Apoptosis – DAP kinase family signaling (Reactome R-HSA-109581)
• p53-independent DNA damage response (KEGG hsa04210)
Protein Summary
STK17B (DRAK2) is a 448-amino acid serine/threonine kinase localized to the nucleus. It contains an N-terminal kinase domain and a C-terminal regulatory region. The protein is activated by autophosphorylation and phosphorylates substrates such as myosin light chain to induce apoptosis. It is highly expressed in lymphoid tissues and plays a critical role in T-cell death. Dysregulation of STK17B is associated with cancer progression and immune disorders.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| STK17B Knockout HEK293 Cell Line | EDJ-KQ6527 | Human | 9262 | Details Get a Quote |
| STK17B Knockout A-549 Cell Line | EDJ-KQ30685 | Human | 9262 | Details Get a Quote |
| STK17B Knockout HCT 116 Cell Line | EDJ-KQ30686 | Human | 9262 | Details Get a Quote |
| STK17B Knockout HeLa Cell Line | EDJ-KQ30687 | Human | 9262 | Details Get a Quote |
Displaying Records 1 To 4 Of 4 Records
